Patterns of Disease Recurrence after SABR for Early Stage Non–Small-Cell Lung Cancer: Optimizing Follow-Up Schedules for Salvage Therapy Naomi E. Verstegen,

Slides:

Advertisements

Similar presentations

Curative Treatment of Stage I Non-Small-Cell Lung Cancer in Patients With Severe COPD: Stereotactic Radiotherapy Outcomes and Systematic Review David.

Advertisements

Su K. Metcalfe, MD, MPH, Michael T

Treatment of stage I NSCLC in elderly patients: A population-based matched-pair comparison of stereotactic radiotherapy versus surgery David Palma, Otto.

Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer Timothy R. Wassenaar, MD, Jens C.

Comparative Effectiveness of Adjunctive Bevacizumab for Advanced Lung Cancer: The Cancer Research Network Experience Debra P. Ritzwoller, PhD, Nikki.

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Two Classic Lyrics Joined by a Contemporary Tune—Environmental Pro-Carcinogen Exposure and Genetic Susceptibility in Lung Cancer Risk Ping Yang, MD,

One in every 14 patients with early-stage lung cancer is not being treated! Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular Surgery

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible Alessandro Brunelli,

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis Matthew Koshy, MD, Renuka Malik,

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D

Outcomes of Hypofractionated High-Dose Radiotherapy in Poor-Risk Patients with “Ultracentral” Non–Small Cell Lung Cancer Hilâl Tekatli, MD, Niels Haasbeek,

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Cornelis J. A. Haasbeek, MD, PhD, Frank J. Lagerwaard, MD, PhD, Ben J

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

The IASLC Lung Cancer Staging Project: The New Database to Inform the Eighth Edition of the TNM Classification of Lung Cancer Ramón Rami-Porta, MD, FETCS,

Electronic Updates for JTO Readers

Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer Masatsugu Hamaji,

Use of Stereotactic Ablative Radiotherapy (SABR) in Non–Small Cell Lung Cancer Measuring More Than 5 cm Hilâl Tekatli, MD, Saar van ’t Hof, MD, Esther.

Stereotactic Ablative Radiotherapy for Centrally Located Early Stage Non–Small-Cell Lung Cancer: What We Have Learned Joe Y. Chang, MD, PhD, Andrea Bezjak,

Joshua E. Rosen, BASc, Michelle C

Patient-Reported Quality of Life After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer Frank J. Lagerwaard, MD, PhD, Neil K. Aaronson,

Pretreatment Anemia Portends Poor Survival and Nonlocal Disease Progression in Patients with Stage I Non–Small Cell Lung Cancer Treated with Stereotactic.

Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer Timothy R. Wassenaar, MD, Jens C.

Frank Detterbeck, MD Journal of Thoracic Oncology

Radiological Changes After Stereotactic Radiotherapy for Stage I Lung Cancer Max Dahele, MBChB, MSc, David Palma, MD, Frank Lagerwaard, MD, PhD, Ben Slotman,

John M. Varlotto, MD, Abram Recht, MD, John C. Flickinger, MD, Laura N

Chris Dickhoff, MD, Max Dahele, MD, PhD, Sayed M

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Telomere Length and Recurrence Risk after Curative Resection in Patients with Early- Stage Non–Small-Cell Lung Cancer: A Prospective Cohort Study Eric.

The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials Krista.

The Central Nervous System as a Sanctuary Site in ALK-Positive Non–Small-Cell Lung Cancer Justin F. Gainor, MD, Sai-Hong Ignatius Ou, MD, PhD, Jennifer.

Follow-Up of Patients after Stereotactic Radiation for Lung Cancer: A Primer for the Nonradiation Oncologist Kitty Huang, MSc, MDCM, David A. Palma,

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations Benjamin Haaland, PhD, Pui San Tan,

Clinical Characteristics and Outcomes for Patients With Thymic Carcinoma: Evaluation of Masaoka Staging Anya M. Litvak, MD, Kaitlin Woo, MS, Sara Hayes,

Variations in Receipt of Curative-Intent Surgery for Early-Stage Non–Small Cell Lung Cancer (NSCLC) by State Helmneh M. Sineshaw, MD, MPH, Xiao-Cheng.

Treatment trends in early-stage lung cancer in the United States, 2004 to 2013: A time- trend analysis of the National Cancer Data Base Kathryn E. Engelhardt,

Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

Re-evaluation of the Role of Postoperative Radiotherapy and the Impact of Radiation Dose for Non–Small-Cell Lung Cancer Using the National Cancer Database

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Incidence and Risk Factors for Chest Wall Toxicity After Risk-Adapted Stereotactic Radiotherapy for Early-Stage Lung Cancer Eva M. Bongers, MD, Cornelis.

Comparative Effectiveness of Adjunctive Bevacizumab for Advanced Lung Cancer: The Cancer Research Network Experience Debra P. Ritzwoller, PhD, Nikki.

Abscopal Effects after Conventional and Stereotactic Lung Irradiation of Non–Small-Cell Lung Cancer Shankar Siva, MBBS, FRANZCR, Jason Callahan, BAppSci,

Early Stage Lung Cancer: Progress in the Last 40 Years

Elizabeth Cathcart-Rake, MD, Ariel Lopez-Chavez, MD, MS

Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios as Prognostic Factors after Stereotactic Radiation Therapy for Early-Stage Non–Small-Cell Lung Cancer

Mirror Mirror on the Wall, Who Is the Fairest of Them All

A1-02: A need to standardize post-operative radiotherapy (PORT) fields used for non- small cell lung cancer (NSCLC): analysis of an international dummy-run.

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

Role of Postoperative Radiotherapy in Nonlocalized Thymoma

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Bolstering the Case for Lobectomy in Stages I, II, and IIIA Small-Cell Lung Cancer Using the National Cancer Data Base Susan E. Combs, MA, Jacquelyn.

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Manoj P. Menon, MD, MPH, Keith D. Eaton, MD, PhD

Pulmonary Atelectasis after Stereotactic Ablative Radiotherapy for a Central Lung Tumor Sashendra Senthi, MBChB, FRANZCR, Eric F Ullmann, MD, Suresh.

Ethnic Differences in the Management of Lung Cancer in New Zealand

Roger Hakimian, MD, Hongbin Fang, PhD, Leno Thomas, MD, Martin J

International Thymic Malignancies Interest Group: A Way Forward

Management of Mediastinal Relapse after Treatment with Stereotactic Body Radiotherapy or Accelerated Hypofractionated Radiotherapy for Stage I/II Non–Small-

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Journal of Thoracic Oncology

Liseth L. van den Berg, MD, Theo J. Klinkenberg, MD, Harry J. M

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

Population-Based Patterns of Surgical Care for Stage IIIA NSCLC in the Netherlands between 2010 and 2013 Chris Dickhoff, MD, Max Dahele, MBChB., PhD,

A Review of First-Line Treatment for Small-cell Lung Cancer

Presentation transcript:

Patterns of Disease Recurrence after SABR for Early Stage Non–Small-Cell Lung Cancer: Optimizing Follow-Up Schedules for Salvage Therapy Naomi E. Verstegen, MD, Frank J. Lagerwaard, MD, PhD, Sayed M.S. Hashemi, MD, Max Dahele, MBChB, PhD, Ben J. Slotman, MD, PhD, Suresh Senan, MRCP, FRCR, PhD Journal of Thoracic Oncology Volume 10, Issue 8, Pages 1195-1200 (August 2015) DOI: 10.1097/JTO.0000000000000576 Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Flowchart of staging and salvage in patients with local recurrences after treatment with SABR for early-stage lung cancer. SABR, stereotactic ablative radiotherapy. Journal of Thoracic Oncology 2015 10, 1195-1200DOI: (10.1097/JTO.0000000000000576) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Flowchart of staging and salvage in patients with a clinical diagnosis of SPLC after treatment with SABR for early stage NSCLC. SPLC, second primary lung cancer; SABR, stereotactic ablative radiotherapy; NSCLC, non–small-cell lung cancer. Journal of Thoracic Oncology 2015 10, 1195-1200DOI: (10.1097/JTO.0000000000000576) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Incidence of SPLC and local recurrences per year in patients treated with SABR for early stage NSCLC. SPLC, second primary lung cancer; SABR, stereotactic ablative radiotherapy; NSCLC, non–small-cell lung cancer. Journal of Thoracic Oncology 2015 10, 1195-1200DOI: (10.1097/JTO.0000000000000576) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions